Biogenero Labs Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
- Paid Up Capital ₹ 2.00 M
- Company Age 15 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 14.37%
- Profit Growth 6.14%
- Ebitda 7.16%
- Net Worth 33.92%
- Total Assets 40.31%
About Biogenero Labs
Biogenero Labs Private Limited (BLPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 23 December 2009 and has a history of 15 years and one month. Its registered office is in Bangaluru, Karnataka, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 2.00 M, as per Ministry of Corporate Affairs (MCA) records.
Malathi Bai and Savitha Velmurugan serve as directors at the Company.
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U24233KA2009PTC051927
- Company No.
051927
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Dec 2009
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
What products or services does Biogenero Labs Private Limited offer?
Biogenero Labs Private Limited offers a wide range of products and services, including Ayurvedic & Herbal Extracts, Plant Extracts, Boswellia Serrata Extract, Pharma Ingredients & Raw Materials, API (Active Pharmaceutical Ingredients), Spices Extracts, Herbal Extracts, Root and Vegetable Extracts, Anti Infective API.
Who are the key members and board of directors at Biogenero Labs?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Malathi Bai  | Director | 01-Dec-2011 | Current |
| Savitha Velmurugan | Director | 30-Sep-2022 | Current |
Financial Performance of Biogenero Labs.
Biogenero Labs Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 14.37% increase. The company also saw a slight improvement in profitability, with a 6.14% increase in profit. The company's net worth Soared by an impressive increase of 33.92%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Biogenero Labs?
In 2021, Biogenero Labs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Biogenero Labs?
Unlock and access historical data on people associated with Biogenero Labs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Biogenero Labs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Biogenero Labs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
